Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.34 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.34 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.34 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2657016 | 0.94 | SIGMAR1 (0.38) | SIGMAR1ALDH1A1CYP2A6KDM1AMAOA | |
| SCHEMBL2657418 | 0.92 | SIGMAR1 (0.41) | SIGMAR1ALDH1A1CYP2A6KDM1AMAOA | |
| SCHEMBL497926 | 0.88 | ALDH1A1 (0.37) | SIGMAR1ALDH1A1CYP2A6KDM1AMAOB | |
| SCHEMBL6688223 | 0.81 | SIGMAR1 (0.45) | SIGMAR1HTR2AHTR2CHTR2BDRD2 | |
| SCHEMBL2658432 | 0.80 | ALDH1A1 (0.39) | SIGMAR1ALDH1A1CYP2A6KDM1AMAOA | |
| SCHEMBL497987 | 0.80 | KDM1A (0.39) | SIGMAR1ALDH1A1KDM1AMAOAMAOB | |
| SCHEMBL8154332 | 0.78 | ALDH1A1 (0.48) | ALDH1A1CYP2A6MAOAMAOBHDAC3 | |
| Styrene SCHEMBL6256107 | 0.74 | ALDH1A1 (0.44) | SIGMAR1ALDH1A1HTR2AHTR2CHTR2B | |
| SCHEMBL498414 | 0.74 | ALDH1A1 (0.40) | SIGMAR1ALDH1A1CYP2A6MAOBHTR2A | |
| SCHEMBL8673109 | 0.72 | SIGMAR1 (0.47) | SIGMAR1HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2786985-A2 | Antagonists of the glucagon receptor | Metabasis Therapeutics, Inc. (US) | 2014-10-08 | — | — | EP | claimed |
| EP-2129654-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | Metabasis Therapeutics, Inc. (US) | 2009-12-09 | — | — | EP | claimed |
| WO-2008098244-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | METABASIS THERAPEUTICS, INC. (US) | 2008-08-14 | — | — | WO | claimed |
| US-10807946-B2 | Antagonists of the glucagon receptor | METABASIS THERAPEUTICS, INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-20190218176-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2019-07-18 | — | — | US | disclosed |
| US-10239829-B2 | Antagonists of the glucagon receptor | METABASIS THERAPEUTICS, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| EP-2786985-B1 | Antagonists of the glucagon receptor | METABASIS THERAPEUTICS INC (US) | 2018-11-28 | — | — | EP | disclosed |
| US-20170275246-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | METABASIS THERAPEUTICS, INC. | 2017-09-28 | — | — | US | disclosed |
| US-9701626-B2 | Antagonists of the glucagon receptor | METABASIS THERAPEUTICS, INC. (US) | 2017-07-11 | — | — | US | disclosed |
| US-20160009639-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | METABASIS THERAPEUTICS INC (US) | 2016-01-14 | — | — | US | disclosed |
| US-9169201-B2 | Antagonists of the glucagon receptor | METABASIS THERAPEUTICS, INC. (US) | 2015-10-27 | — | — | US | disclosed |
| EP-2786985-A2 | Antagonists of the glucagon receptor | Metabasis Therapeutics, Inc. (US) | 2014-10-08 | — | — | EP | disclosed |
| US-20140135400-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | METABASIS THERAPEUTICS, INC. (US) | 2014-05-15 | — | — | US | disclosed |
| US-8710236-B2 | Antagonists of the glucagon receptor | METABASIS THERAPEUTICS, INC. (US) | 2014-04-29 | — | — | US | disclosed |
| US-20120214769-A1 | Novel Antagonists of the Glucagon Receptor | METABASIS THERAPEUTICS, INC. (US) | 2012-08-23 | — | — | US | disclosed |
| EP-2129654-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | Metabasis Therapeutics, Inc. (US) | 2009-12-09 | — | — | EP | disclosed |
| WO-2008098244-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | METABASIS THERAPEUTICS, INC. (US) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160009639-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | GLP1R, GCGR, GPR119 | SIGMAR1 674/4885ALDH1A1 4642/4885CYP2A6 2324/4885 |
| US-20190218176-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | GLP1R, GCGR, GPR119 | SIGMAR1 659/4885ALDH1A1 4644/4885CYP2A6 2368/4885 |
| US-10239829-B2 | Antagonists of the glucagon receptor | GLP1R, GCGR, GPR119 | SIGMAR1 768/4885ALDH1A1 4662/4885CYP2A6 2195/4885 |
| US-20140135400-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | GLP1R, GCGR, GPR119 | SIGMAR1 674/4885ALDH1A1 4642/4885CYP2A6 2324/4885 |
| US-20120214769-A1 | Novel Antagonists of the Glucagon Receptor | GLP1R, GCGR, GPR119 | SIGMAR1 674/4885ALDH1A1 4642/4885CYP2A6 2324/4885 |
| US-20170275246-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | GLP1R, GCGR, GPR119 | SIGMAR1 674/4885ALDH1A1 4642/4885CYP2A6 2324/4885 |
| US-10807946-B2 | Antagonists of the glucagon receptor | GLP1R, GCGR, GPR119 | SIGMAR1 729/4885ALDH1A1 4657/4885CYP2A6 2151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.